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Gy (2.2 Gy/day) to the clinical target volume for tumor and 
metastatic nodal station, 54 Gy (1.8 Gy/day) to the clinical 
negative neck region concomitantly in 30 fractions. 
Concurrent chemotherapy was given to 32 pts (cisplatin 75-
100 mg/m²/21 days for 25 pts, cisplatin 30-40 mg/m²/week 
for 5 pts and Cetuximab for 2). Possible correlation between 
Overall Cancer specific (OS) and GTV-PET Volumes (GTV-T+N, 
GTV-T, GTV-N) was also considered. 
 
Results: The median follow-up was 39.2 months (range: 3-
125); 27%, 62% and 11% pts has respectively never smoked, a 
smoking history of more than 10 packs/year and not assessed. 
36 pts completed the treatment as scheduled. Temporary 
treatment interruption due to acute toxicity, mainly 
mucosae, was observed in 5 patients. No grade 4 acute 
mucosae and skin toxicity was reported. Seventeen pts (46%) 
experienced grade 3 toxicity, mostly dermatitis and 
mucositis. Late grade 3 and 2 xerostomia was seen 
respectively in 3% and 32% pts. No grade 4 late toxicity was 
observed. The 3-year OS, Local disease-free Tumor (LTC), 
Local disease-free Nodal (LNC) and distant metastasis-free 
(DMFS) survivals were 87%, 83%, 89% and 92% respectively. 
Multivariate Cox regression analyses revealed that GTV-T+N 
and GTV-T are predictors for OS with a best-cut-off value 
equal to 30.9 cc (p=0.005) and 22.4 cc (p=0.038). 
 
Conclusion: The slightly accelerated dose escalation in 
oropharyngeal cancers to 18FDG-PET positive tumour sub-
volumes is likely to be safe even with concurrent 
chemotherapy. Very interesting 3-year OS and loco-regional 
disease control rate are obtained. The results of the present 
study suggest that GTV-PET has a predictive value for the SIB-
HT outcome. These findings may constitute the basis for 
more personalized treatments.  
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Purpose or Objective: There are limited and heterogeneous 
data on prognostic factors of locally advanced epithelial non 
glandular sinonasal cancer (ESNC) treated with multimodal 
treatment strategy. Prognosis of ESNC remains poor, with an 
overall 5-year survival rate of 30–50%. We analyzed a 
retrospective series of consecutive patients (pts) treated 
with IMRT at our institution, with a specific focus on the 
prognostic implications of clinical and treatment-related 
factors. 
 
Material and Methods: Since 2007, 49 pts with ESNC staged 
III and IVA-IVB were treated at our Institution. Histology was 
squamous cell carcinoma (SCC) in 22 pts (44.9%), 
undifferentiated carcinoma (SNUC) in 20 pts (40.8%) and 
neuroendocrine carcinoma (SNEC) in 7 pts (14.3%). Prevalent 
primary site was ethmoid sinus (24 pts, 49%). Thirteen pts 
(26.5%) had N stage ≥2b and 12 (24.5%) had positive 
retropharyngeal nodes (RPNs). Orbital apex invasion (OAI), 
nasopharyngeal involvement, gross nerves involvement (GNI) 
and positive surgical margins (R1) were found in 24 (49%), 12 
(24.5%), 10 (20.4%) and 5 (10.2%) pts respectively. Thirty 
(61.2%) and 19 (38.8%) pts received definitive and 
postoperative IMRT, respectively. Thirtyfive pts (71.5%) 
received induction chemotherapy before surgery or RT 
and/or concomitant CHT. Thirtyeight pts (77.5%) received 
concomitant CHT. IMRT was given with standard fractionation 
at a total dose of 65-72 Gy in definitive cases and 54-66 Gy in 
adjuvant cases, according to histological findings. Gross 
tumor volume (GTV) was defined in all radical pts, and dose-
volume histograms to all targets were analyzed in all pts. 
 
Results: Median follow up was 22.4 months (range 6-85). 
Three-year overall survival (OS), disease free survival (DFS) 
and locoregional control (LRC) were respectively 66.5%, 
55.4% and 66.3% for the entire cohort. OS and DFS were 
statistically better in pts with SCC or SNUC compared to pts 
with SNEC, in pts with ethmoid primary compared to other 
sites, in pts with N0 compared to pts with N stage ≥ 2b, in pts 
with RPNs compared to pts without RPNs (see Fig. 1), in pts 
with OAI compared to pts without OAI and in pts with GNI 
compared to pts without GNI. LRC was better even though 
statistically not different in pts without R1 compared to pts 
with R1. A multivariate analysis showed that ethmoid as 
primary origin site was a positive independent prognostic 
factor on OS, whereas RPNs positivity and OAI were negative 
independent prognostic factors for OS. For pts receiving 
definitive IMRT, pts with GTV <79.7cc had better OS, DFS and 
LRC compared to pts ≥79.7 cc, even if the difference was not 
statistically significant. Dosimetric factors were not found to 
have any prognostic role. 
 
 
 
Conclusion: In a monoinstitutional series of locally advanced 
ESNC we obtained a 66.5% 3-yr OS and a 55.4% 3-yr DFS. We 
were able to identify RPNs involvement, ethmoid primary site 
and OAI as independent prognostic factors.  
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Purpose or Objective: To compare early tumor response and 
compliance of locally advanced head and neck cancer 
patients receiving concurrent chemo-radiation, weekly 
Cisplatin with conventional fractionation versus weekly 
Cisplatin with accelerated fractionation and to assess toxicity 
profile 
 
Material and Methods: Patients with histologically confirmed 
primary head and neck squamous cell carcinoma, stage III and 
IV (Oral cavity, oropharynx, hypopharynx and larynx) 
attending the department of Radiotherapy, Father Muller 
Medical College Hospital, Mangalore Between November 2013 
to April 2015. 
Total of 64 patients were recruited and randomized into 
conventional and accelerated arm each having 32 patients. 
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Both the arms received concurrent chemo-radiation. 
Chemotherapy with inj Cisplatin 35 mg/m² weekly IV infusion 
was given as a radiosensitizer before Radiotherapy for 6 
cycles and external beam radiotherapy 69.99-70Gy in 33-35 
fractions 2 - 2.121Gy/fraction using Linear accelerator of 6MV 
photons by Conventional arm received standard regimen 5 
fractions/week with overall treatment time of 6 weeks and 
Accelerated arm received 6fractions/week with overall 
treatment time of 7weeks.  
Patients were evaluated in both the arms for early tumor 
response and acute Toxicities 
 
Results: The mean age of patients were 53.44 
years,76.60%were male and 23.4% were female . 
Concurrent chemoradiation using accelerated fractionation 
showed higher percentage of complete response rate , in 
stage III-100%, IVA-88.50%and IVB- 50%,were as in 
conventional fractionation it was in stage III-87.50% and IVA-
80.00%. 
According to site complete response rate in oral cavity 
87.50%and 50.00% , oropharynx 92.90% and 72.70% in 
accelerated fractionation and conventional fractionations 
respectively. 
Total number of cycles of chemotherapy received were same 
in both the arms. There was significant weight loss during 
treatment in accelerated fractionation compared to 
conventional fractionation arm. 
 
Conclusion: In our study, Locally advanced head and neck 
cancers showed better early tumor response with acceptable 
acute toxicities when treated with concurrent 
chemoradiation using accelerated fractrationation compared 
to conventional fraction and the quality of life was not 
stastically different in both the arms. 
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Purpose or Objective: It is established that in the 
management of locally advanced head and neck cancer (HNC) 
patients, 18F-FDG-PET/CT (FDG) plays a significant role in 
the pre-treatment setting to predict outcome and prognosis 
and at the end of the chemo-radiotherapy (CRT) to assess the 
tumor response. This systematic review aims to evaluate the 
use of FDG acquired during CRT, ad interim FDG (FDGint), 
with the aim to identify tumor responsiveness in an early 
stage of the treatment in order to allow modification of the 
treatment plan and/or to setup alternative therapeutic 
strategies to enhance the therapeutic ratio.  
 
Material and Methods: Data search was performed in PubMed 
for full original papers published from 2005 up to August 
2015, written in English and based on the use of 3D hybrid 
PET/CT only, with eight different combination of keywords. 
The literature search brought 568 articles. Twenty-one 
original papers fulfilled the inclusion criteria: 8 studies 
investigated the predictive role of FDGint assessing 
correlations between metabolic variations and clinical 
outcomes, 7 studies draw conclusions about a potential role 
of response assessment during RT for treatment adaptation 
without reporting any correlation with the clinical data, and 
6 studies were focused on the use of FDGint for biology-
guided adaptive RT. 
 
Results: The results of the analysis considering only the 
papers focusing on the predictive role of FDGint are reported 
in the table. All patients underwent at least a FDG at 
baseline, and one at a dose in the range of 10-20 Gy (early 
PETint), or in the range of 40-50 Gy (late PETint). Most of the 
studies reported a qualitative or semi-quantitative method of 
delineation of the FDG uptake, using a threshold value of the 
SUVmax, usually 40% or 50%. All the studies have in common 
the SUVmax and its variation as the main parameters 
considered for FDG evaluation, although the largest and first 
study evaluating all metabolic parameters of FDGint, found 
that tumor lesion glycolysis was a better and statistically 
more significant predictor of outcome than SUVmax. Two 
papers comparing FDGint with FLTint revealed that reduced 
FLT SUV preceded reduced FDG uptake, suggesting that 
FLTint is expected to assess the therapeutic response much 
earlier than FDGint. 
 
 
 
Conclusion: Most of the works confirmed the value of FDGint 
in predicting the response to CRT, while few highlighted the 
poor prognostic value of FDGint compared to FDG acquired 2-
3 months after the end of CRT which revealed a strong 
correlation with local and regional control and with survival. 
Although the best timing to assess tumor response during RT 
remains a matter of debate, the two week time point seems 
most favorable, also because there is still sufficient 
opportunity for adaptation of the treatment strategy. Such 
contradictory findings deserve to be further analyzed and 
confirmed in a more numerous and homogeneous series 
according to the tumor site and radio-chemotherapy 
schedules. 
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